Eli Lilly & LLY · NYSE Pharmaceutical Preparations · Fiscal year ends Dec 31
annual quarterly
Last 5 fiscal years
Revenue and net income $0 $20B $40B $60B $80B Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025 Income statement Fiscal year Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025 Revenue $28.3B $28.5B $34.1B $45B $65.2B Cost of revenue $7.3B $6.6B $7.1B $8.4B $11.1B Gross profit $21B $21.9B $27B $36.6B $54.1B Research & development $6.9B $7.2B – – – Selling, general & admin $6.4B $6.4B $7.4B $8.6B $11.1B Interest expense $340M $332M $486M $781M $895M Pre-tax income $6.2B $6.8B $6.6B $12.7B $25.7B Income tax $574M $562M $1.3B $2.1B $5.1B Net income $5.6B $6.2B $5.2B $10.6B $20.6B Diluted EPS 6.12 6.90 5.80 11.71 22.95 Diluted shares 912M 905M 903M 904M 899M
Balance sheet Fiscal year Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025 Cash & equivalents $3.8B $2.1B $2.8B $3.3B $7.3B Receivables $6.7B $6.9B $9.1B $11B $17.8B Inventory $3.9B $4.3B $5.8B $7.6B $13.7B Current assets $18.5B $18B $25.7B $32.7B $55.6B Net PP&E $9B $10.1B $12.9B $17.1B $24.7B Goodwill $3.9B $4.1B $4.9B $5.8B $5.9B Total assets $48.8B $49.5B $64B $78.7B $112B Payables $1.7B $1.9B $2.6B $3.2B $5.4B Deferred revenue $263M $219M $194M $166M – Current liabilities $15.1B $17.1B $27.3B $28.4B $35.2B Short-term debt $1.5B $1.5B $6.9B $5.1B $1.6B Long-term debt $16.7B $14.8B $19.1B $29.5B $40.9B Shareholders' equity $9B $10.6B $10.8B $14.3B $26.5B
Cash flow Fiscal year Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025 Operating cash flow $7.4B $7.6B $4.2B $8.8B $16.8B Depreciation & amortisation $1.5B $1.5B $1.5B $1.8B $2B Stock-based compensation $343M $371M $629M $646M $626M Acquisitions $747M $327M – – – Share buybacks $1.3B $1.5B $750M $2.5B $4.1B Dividends paid $3.1B $3.5B $4.1B $4.7B $5.4B Dividend per share 3.53 4.07 4.69 5.40 6.23
Key ratios Fiscal year Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025 Revenue growth (YoY) – 0.8% 19.6% 32.0% 44.7% EPS growth (YoY) – 12.7% −15.9% 101.9% 96.0% Gross margin 74.2% 76.8% 79.2% 81.3% 83.0% Net margin 19.7% 21.9% 15.4% 23.5% 31.7% Return on equity 62.2% 58.6% 48.6% 74.2% 77.8% Cash conversion (CFO ÷ net income) 1.32x 1.21x 0.81x 0.83x 0.81x Receivable days 86 88 97 89 99 Inventory days 194 237 298 329 454 Payable days 83 106 134 140 178 Debt ÷ equity 2.04x 1.53x 2.41x 2.42x 1.60x Net debtDebt − cash & equivalents; excludes investments; negative = net cash $14.5B $14.2B $23.2B $31.3B $35.2B Current ratio 1.23x 1.05x 0.94x 1.15x 1.58x
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.